IQVIA

Overview

IQVIA is the dominant global healthcare data, analytics, technology, and clinical-research platform for life sciences. The 2016 IMS Health / Quintiles merger created a vendor that spans commercial data, real-world evidence, patient analytics, commercial engagement, and CRO execution at a scale few pharma services companies can match.

For a launch or market-access team, IQVIA should not be evaluated as only a data feed. It is usually four vendor decisions in one: commercial data and analytics, RWE and patient finding, clinical-research execution, and AI-ready data infrastructure. That breadth is the point, but it also means the RFP has to define which operating workflow IQVIA is being hired to improve.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, IQVIA is evaluated as a global healthcare data, analytics, technology, and clinical-research platform for life sciences.

Capability	Buyer should compare	IQVIA readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Major data foundation. IQVIA’s NPA, Xponent, MIDAS, OneKey, longitudinal claims, EMR, and RWE assets remain foundational inputs for many commercial and evidence workflows.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Major analytics use case. Best fit when a team needs prescription / claims / patient analytics connected to field, access, launch, or medical-affairs execution. Major evidence work. IQVIA belongs in CRO and RWE shortlists when global scale, data assets, and clinical-to-commercial continuity matter.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Mixed. IQVIA is stronger as a data and workflow layer than as the CRM owner; OCE customers have a managed path as IQVIA works with Salesforce and Veeva ecosystems.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Not the main buying reason for IQVIA; validate only if the SOW includes provider, payer, and pharmacy network connectivity.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Emerging strength. The diligence question is whether the AI use case is grounded in a licensed IQVIA data asset or workflow that the manufacturer will actually operationalize.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Required governance control. Validate permitted uses, refresh cadence, geography, de-identification, audit logs, and downstream sharing rights by data product.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Major reporting layer. DaaS+ and Connected Intelligence are the public packaging for more integrated data delivery.

Buyer Fit

• Best-fit motion: IQVIA should be high on the list when a manufacturer wants enterprise-grade commercial data, RWE, patient analytics, or CRO execution connected to a broader operating model.
• Best-fit scenarios: Launch planning, HCP / account targeting, patient finding, market sizing, real-world evidence, global trial operations, patient solutions, and commercial analytics that need high data coverage.
• Where to be careful: Smaller studies, narrow therapy-area needs, or buyer teams that want a specialist partner with senior-team attention may prefer a focused CRO, RWE, or patient-services vendor.
• Commercial fit: Expect enterprise subscription / services scoping with explicit data rights, service levels, integration requirements, and governance obligations.
• Scope discipline: Decide early whether IQVIA is acting as the system of record, data supplier, analytics layer, CRO, patient-solutions partner, or integration partner; bundled breadth can create overlap with incumbent CRM, hub, data-lake, and clinical vendors.
• Program diligence: Confirm source data rights, refresh cadence, integration effort, field / hub / CRM workflow fit, AI governance, and whether IQVIA is replacing or augmenting existing systems.

Differentiators

• Data moat: NPA, Xponent, MIDAS, OneKey, claims, EMR, and RWE assets give IQVIA a breadth of commercial and patient-level signal that few competitors can replicate globally.
• Clinical-to-commercial bridge: The same vendor can support trial execution, site / patient recruitment, RWE, commercial analytics, and post-launch performance tracking.
• Commercial Solutions breadth: Patient solutions, analytics, consulting, commercial engagement, and commercial technology can be packaged together for manufacturers that want fewer vendors.
• Partner posture: The Veeva partnership and Salesforce OCE licensing indicate IQVIA is prioritizing data monetization and ecosystem integration over trying to own every engagement layer.
• AI-ready data foundation: IQVIA’s most credible AI story is governed agentic workflow built on proprietary data, not generic chatbot functionality.

RFP Questions

• Which data sources and rights are included in the contract, and which require separate licensing?
• How does the platform integrate with CRM, hub, claims, EHR, and data-lake environments already in place?
• Which modules are mandatory, which are optional, and what can be carved out to avoid duplicating incumbent Veeva, Salesforce, hub, CRO, or analytics infrastructure?
• What workflow decisions are automated, and what human review remains required for regulated or patient-impacting activity?
• Which CRO delivery leads are the named delivery leads, what turnover protections apply, and how are change orders / pass-through costs governed?
• Which site-selection, patient-recruitment, and RWE claims can be proven with recent, therapy-relevant case evidence?
• How are model performance, data refresh, privacy controls, data-use rights, and audit logs governed over time?

Recent Activity

• Q1 2026 results: IQVIA reported continued growth across Commercial Solutions and R&D Solutions, with investor materials emphasizing commercial analytics, patient solutions, R&DS bookings, and AI-enabled workflows.
• 2026: IQVIA.ai / agentic workflows: Public company materials position IQVIA.ai as a life-sciences AI layer tied to the company’s data, analytics, and clinical/commercial operating workflows.
• Segment restructuring: Effective January 1, 2026, CSMS was absorbed into TAS and renamed Commercial Solutions; selected real-world late-phase offerings moved into R&DS.
• 2026: DaaS+ launch: IQVIA introduced Data as a Service Plus as an integrated delivery model for multiple IQVIA data sources.
• 2026: Ecosystem moves: IQVIA’s Veeva partnership, Salesforce OCE licensing path, AWS collaboration, NVIDIA collaboration, and Cedar Gate acquisition all point to a strategy of keeping IQVIA data central across partner platforms.